Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 8Sarcoma 2

Conditions

Sarcoma 168Gliosarcoma 134Glioblastoma 130Brain Neoplasms 101Astrocytoma 86Central Nervous System Neoplasms 77Osteosarcoma 65Oligodendroglioma 61Neuroblastoma 58Sarcoma, Kaposi 56Glioma 51Neuroectodermal Tumors, Primitive, Peripheral 48Dendritic Cell Sarcoma, Interdigitating 44Burkitt Lymphoma 44Rhabdomyosarcoma 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 40Lymphoma 39Wilms Tumor 37Medulloblastoma 35Lymphoma, Non-Hodgkin 35Recurrence 32Sarcoma, Ewing 31Acquired Immunodeficiency Syndrome 30Lymphoma, Large B-Cell, Diffuse 29HIV Infections 29Ependymoma 28Leukemia 27Gastrointestinal Stromal Tumors 27Melanoma 26

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Endometrial Adenocarcinoma × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT00478426 2020-02-17

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
34 enrolled 10 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡